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Abstract
Background and aims: miRNAs, as a class of non-coding RNAs, take part in different cellular processes. Dysregulation of different miRNAs 
has been reported in numerous disorders to date. Multiple sclerosis (MS) is an autoimmune disease with high prevalence in Iran and Th17 
cells play an important role in its pathogenesis. In the current study, we aimed to predict the possible role of miR-34a and miR-215 in the 
process of controlling Th17 differentiation, and hence, their possible impact on the onset and progression of MS.
Methods: We investigated probable interactions of miRNAs and genes that participate in Th17 cells differentiation using miRwalk database 
as an integrative one which utilizes 10 different algorithms to predict miRNA-mRNA interaction.
Results: Based on our findings, miR-34a and miR-215 were predicted to have a potential role in the induction of Th17 cells differentiation. 
Conclusion: Conclusively, miR-34a and miR-215 may up-regulate Th17 cells of MS patients. Since bioinformatics data have shown that 
these miRNAs suppress negative regulatory genes in Th17 cells differentiation, we suppose that down-regulation of these miRNAs could 
ameliorate MS symptoms. Therefore, several therapeutic approaches may be considered for these miRNAs besides their application as 
valuable prognostic/diagnostic biomarkers in detection of various stages of MS.
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Introduction 
Multiple sclerosis (MS) is a common disease of the central 
nervous system, which occurs in young and middle-aged 
people (1). The prevalence rate of MS is about 1-2 in 
1000, and this rate appears to be rising (2). This disease 
usually begins around the age of 30 and causes a series 
of disabilities in people. The incidence of this disease in 
women is twice as high as in men. However, men and 
women have the same prevalence in the primary progressive 
state of the disease. The main cause of this disease is not 
well known, but it seems that a combination of genetic 
and non-genetic factors such as virus, metabolism, or 
environmental factors may be involved, which lead to this 
autoimmune disorder (3). Isfahan province is one of the 
areas for which a moderate to high incidence of this disease 
has been reported, and studies show that the growth rate 
of this disease in Isfahan is increasing (4).
There are several phenotypes or patterns of the disease 
progression. These phenotypes include the following 
four subgroups. In the relapsing-remitting phenotype, 
the disease relapses unpredictably and then enters a 
silent phase without symptoms of a disease for several 
months or years. About 85% of MS patients initially 
show a relapsing-remitting form at the end of the second 
decade of their life (5). Additionally, 65% of people with 
relapsing-remitting phase develop a new phase of the 
disease called the secondary progression a few years after 
the onset of the disease, in which improving symptoms 
disappear and nervous problems increase (6). The primary 
progressive phenotype accounts for about 10%-20% of 
the affected population, with apparently no improvement 
in these people from the onset of the disease. Moreover, 
primary progressive MS tends to have a later age of onset 
than relapsing-remitting MS. The relapsing-remitting is a 
rare form of the disease in which patients develop a lasting 
neurological damage from the beginning of the disease 
                                                              Journal of Shahrekord University of Medical Sciences, Volume 21, Issue 6, 2019 277
       Impact of miR-34a and -215 on differentiation of Th17 cells 
(7). Studies show that Th17 cells play an important role in 
the incidence of symptoms of many autoimmune diseases, 
including MS. Th17 cells are subtypes of CD4+ T cells and 
play a role in the development of an autoimmune disease 
as a part of the adaptive immune system by producing 
IL-17A, IL-17F, IL-21, IL-22, and GM-CSF interleukins 
in the defense against extracellular infections caused by 
fungi and bacteria. IL-17 produced by Th17 cell induces 
proinflammatory cytokines and also proinflammatory 
chemokines that increase the chemotactic activity of 
inflammatory cells at the site of inflammation (9).
Studies have shown that by influencing the IL-17 pathway, 
the disease severity can be reduced (8-10). MiRNAs, a 
new group of non-coding and single-stranded RNAs with 
a length of approximately 22 nucleotides, are found in 
plants, animals, and some viruses. They are involved in 
shutting down RNA and regulating gene expression at 
the post-transcriptional level (11). These RNAs exert their 
effect by regulating and controlling the gene expression at 
the post-transcriptional level of mRNA. Therefore, they 
bind to the 3’-UTR region of their target protein and cause 
the destruction and inhibition of mRNA translation of 
their target protein (12). It has been observed that miRNAs 
play an important role in regulating the immune response. 
To date, few of the specific miRNAs that are important in 
regulating immune responses have been discovered or their 
role has been investigated (13).
The purpose of this study is to determine the 
bioinformatics of miRNAs that have the greatest effect on 
the differentiation pathway of Th17 cells.
Materials and Methods
This is a theoretical bioinformatics study that has been 
carried out using the miRWalk database. This study 
includes three sections of data collection from scientific 
papers, data analysis in the miRWalk database, and finally, 
the study of the results and conclusions, and the process 
is presented below. To date, many studies have been 
conducted to explore the signaling pathways involved in 
the differentiation of Th17 cells, and many of the positive 
and negative regulatory genes involved in this pathway 
have been identified. A series of these genes are considered 
as positive regulators and lead to differentiation into Th17 
cells, which include IL-6, IL-23, STAT3, SMAD6/7, 
RORc, and mTOR. Some of them are also negative 
regulators, such as SOCS3, TSC1, SMAD2, and FOXP3, 
which direct the differentiation path toward other T cells, 
such as Th1, Th2, or Treg (14, 15) (Table 1).
The miRwalk database is a miRNA-mRNA interaction 
database that allows the simultaneous comparison of the 
prediction outcomes of the nine other miRNA-mRNA 
interaction databases. Therefore, if each of the ten miRNA-
mRNA interaction databases predicts the likelihood of a 
mutant, 1 is placed in front of that database, otherwise, 0 
is placed in front of it; therefore, each host finds a number 
from 0 to 10 that represents the number of databases 
that have predicted the probability of generating that 
interaction. In this method, interactions that have been 
confirmed through laboratory methods receive number 
of 5 or higher, which itself is evidence of the validity 
and reliability of this bioinformatic prediction method. 
Other bioinformatic databases that predict the miRNA-
mRNA interactions include 1-DIANA-mT, 2-miRanda, 
3-miRDB, 4-miRwalk, 5-RNAhybride, 6-PICTAR, 
7-PITA, 8- RNA22, 9-TargetScan, and 10-miRwalk. In 
order to predict miRNAs involved in the differentiation 
of the Th17 subtype, first, a list of miRNAs expressed in 
blood samples, peripheral blood mononuclear cells, or 
tissues involved in various autoimmune diseases that had 
expression change and were proposed in at least two studies 
was prepared and then, using the miRwalk database, 
its inhibitory effect was investigated on the positive and 
negative regulators of Th17 subtype differentiation.
Results
Based on this study, we found that miR-215 and miR-
34a could be proposed as the regulators involved in 
the differentiation of Th17 and instigation of MS. In 
examining miRNA-mRNA interactions, only those that 
were approved by at least 6 databases were considered.
The results indicate that miR-215 induces this cell line 
with its inhibitory effect on the negative regulators of the 
differentiation pathway to Th17 cells. The target miRNAs 
of this miRNA include SMAD2, TSC1, and SOC3 (16-
21). The miR-34a precursor is transcribed on human 
chromosome 1. The precursors of miR-34b and miR-34c 
are transcribed on a region of human chromosome 11. The 
miR34a causes apoptosis of human white blood cells by 
inhibiting SIRT1 (20). This miRNA also plays a role in 
the differentiation of human B lymphocyte cells, which 
is adapted from other immune system cells. The miR-
34a, like the previous miRNA, plays a role in the process 
of inhibiting the negative regulators of differentiation of 
Th17 cells. Negative regulators that are the target of this 
miRNA include SOCS3, PIAS3, and FOXP3 (22). The 
genes inhibited by these miRNAs are briefly illustrated in 
Figure 1.
Discussion
Th17 cells are a subset of the CD4+ T cell line, whose 
role is protecting against extracellular infections caused 
by bacteria and fungi. Moreover, they play a role in the 
pathogenesis of autoimmune diseases such as MS (23). 
Therefore, the possible role of miR-34a and miR-215 in 
the process of differentiation of Th17 cells in patients with 
MS was proposed in the present study. Among the target 
factors of these two miRNAs are SMAD2, FOXP3, PIAS3, 
and SOCS3 that are the inhibitors of differentiation of 
naive T cells to Th17 cells. The performances of some of 
them are briefly reviewed below. 
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Studies show that SMAD2/3/4 transcription factors in 
the active form can bind to the FOXP3 promoter and 
induce its expression; therefore, the cytokine TGFβ acts on 
the induction of differentiation of the iTreg cell subtype. 
FOXP3 acts as one of the Th17 subtype inhibitors (24).
STAT proteins have a major role in the process of 
differentiating a variety of CD4+ subtypes, each of which 
pushes the differentiation pathway into a specific subtype 
and inhibits differentiation into other subtypes. STAT3, 
STAT4, STAT5, and STAT6 are effective in the process 
of Th17, Th1, Treg, and Th2 differentiation, respectively 
(25).
Other factors that inhibit Th17 subtype differentiation 
in relation to the cytokine signaling pathway include 
the suppressor of cytokine signaling 3 (SOCS3) and the 
PIAS3 ligase. The SOCS3 protein is expressed under the 
influence of cytokine signals of IL-6, IL-21, IL-23 and 
by the STAT3 transcription factor, and acts as a negative 
regulator of STAT3 activity. Generally, SOCS proteins 
are one of the most important regulating proteins of the 
expression of STAT-dependent genes that in fact create 
a negative feedback in the STAT signaling pathway. 
Moreover, the specific deletion of SOCS3 in CD4+ T cells 
is associated with an increase in phosphorylation of STAT3 
and production of IL-17 (26).
Junker et al reported that the miR-34a expression 
is increased in the active phase (relapse) of MS (27). 
Increased expression of miR-34a has been seen in the 
white matter of MS patients (27). On the other hand, the 
increased expression of this miRNA has been observed 
in rheumatoid arthritis and inflammatory bowel disease 
(28,29). It has been observed in a study that the level of 
miR-215 expression in active plaques in MS patients 
has increased, while no change has been observed in its 
expression in other studies (30). In a recent study, the 
increase of miR-34a in a group of MS patients has been 
reported, which is correlated with increased number of 
Th17 cells (31). All the above-mentioned studies confirm 
our findings. Differences in the methods of study and the 
samples examined can be the cause of these differences 
in the results of the studies. Various studies show that in 
patients with MS, these miRNAs can be used as biomarkers 
to detect the disease in the early stages or before the onset 
of clinical symptoms in the person. Therefore, a significant 
increase in the expression of these miRNAs in the blood can 
be regarded as a biomarker to diagnose the severity of the 
disease or the activity level of Th17 cells. It is also predicted 
that the expression of these miRNAs in the T-cells of the 
affected individuals has increased, which in turn increases 
the population of the Th17 cells, and accordingly, by 
reducing the expression of this miRNA by, for example, 
the miRNA inhibitor in naive CD4+ T cells, it is possible 
to inhibit the differentiation towards the Th17 cells and 
reduce the severity of the disease in this way.
Conclusion
In this study, we showed the probability of the role of 
miR-215 and miR-34a in differentiation of T cells towards 
Th17 cells by inhibiting transcription factors. With the 
help of miR-215 and miR-34a inhibitors, treatment in 
this field can be achieved, or the miRNA itself can be used 
as a biomarker for the diagnosis of MS. However, further 
and detailed experimental studies are needed to prove these 
suggested roles for miR-215 and miR-34a.
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Note. These regulators can inhibit or induce differentiation into Th17 cells 
through different pathways (16, 17).
Figure 1.miRNA-mRNA interaction based on the miRWalk database . 
Note. In this Figure, the dots represent the potential targets for each 
miRNA. Red squares represent regulators for differentiation of Th17 
cells that are likely affected by miRNAs. The black lines show an 
interaction between the miRNA and their target genes.
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